GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced results from a pilot clinical study which demonstrated the substantially enhanced weight loss effects of combining the company's EndoBarrier Gastrointestinal Liner with a new EndoBarrier Flow Restrictor.